**ISPOR Russia St. Petersburg Chapter**

**Annual Report 2020**

To: Board of Directors

International Society for Pharmacoeconomics and Outcomes Research

505 Lawrence Square Boulevard

South Lawrenceville, ТО 08648 USA

**PREPARED BY**

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University.

Yulia E. Balykina, PhD, associate professor, St Petersburg State University, faculty of Applied Mathematics and Control Processes.

**President of ISPOR Russia St. Petersburg Regional Chapter**

Alexey S. Kolbin, MD, PhD, Doctor of Science, Professor, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University, St. Petersburg, Russia

**President-Elect**

Sergey K. Zyryanov, MD, PhD, Professor, Head of the Department of Clinical Pharmacology of the RUDN University, Moscow, Russia

**Director**

Dmitry Yu. Belousov, Science Editor “Good clinical practice”, Moscow, Russia

**Secretary**

Alexey A. Kurylev, MD, Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

For more information on the Chapter, please visit at ***https://www.ispor.org/member-groups/global-groups/regional-chapters/russia-st-petersburg***

**Activities of the Chapter in 2020:**

**I. Publications in the Field of Pharmacoeconomics and Health Technology Assessment**

|  |  |  |  |
| --- | --- | --- | --- |
| № | Title | Journal | Authors |
| 1 | Pharmacoeconomics of JAK inhibitors in patients with rheumatoid arthritis who had inadequate response to conventional synthetic disease- modifying antirheumatic drugs | Clinical Pharmacology and Therapy. 2020;29(3):67-72. DOI 10.32756/0869- 5490-2020-3-67-72 | Rudakova A.V. |
| 2 | Economic consequences of mandatory price re-registration for medicines from the high-cost nosology program | Good Clinical Practice. 2020;(3):27-33. DOI: 10.37489/2588-0519-2020-3-27-33 | Rudakova A.V., Ugrekhelidze D.T., Krylov V.A. |
| 3 | Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment | Oncohematology. 2020;15(1):73-81. DOI: 10.17650/1818-8346-2020-15-1-73-82 | Rudakova A.V., Stadnik E.A. |
| 4 | Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2 | Good Clinical Practice. 2020;(3):4-14. DOI: 10.37489/2588-0519-2020-3-4-14 | Dyakov I.N., Zyryanov S.K. |
| 5 | Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis | Good Clinical Practice. 2020;(3):15-26. DOI: 10.37489/2588-0519-2020-3-15-26 | Krysanov I.S., Krysanova V.S., Karpov O.I., Ermakova V.Yu. |
| 6 | The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus | Good Clinical Practice. 2020;(5):4-14. DOI: 10.37489/2588-0519-2020-5-4-14 | Dyakov I.N., Zyryanov S.K. |
| 7 | A method for rapid assessment of the risk of type 2 diabetes mellitus or prediabetes in the Russian population | Patent No. 2730949 dated 19.03.2020 | Shestakova M.V., Kolbin A.S., Galstyan G.R., Arepyeva M.A., Zaitseva E.L., Mayorov A.Yu., Karpov O.I., Proskurin M.A., Kurylev A.A., Dedov I.I. |
| 8 | Assessment of manifestations and prediction of morbidity in the North-West of Russia | Preventive and Clinical Medicine. 2020;74(1):51-57. | Vetrov V.V., Lyalina L.V., Plavinskii S.L., Historik O.A. |
| 9 | Clinical and economical effectiveness of interferon gamma combined with chemotherapy in treatment of advanced and metastatic melanoma | Preventive and Clinical Medicine. 2020;74(1):58-63. | Plavinskii S.L., Shabalkin P.I. |
| 10 | Estimating burden of disease due to continuous propagation of HIV infection among injecting drug users | HIV Infection and Immunosuppressive Disorders. 2020;12(1):97-104. DOI: 10.22328/2077-9828-2020-12-1-97-104 | Barinova A.N., Lebedeva A.A., Ladnaya N.N., Zaytseva E.E., Plavinskii S.L. |
| 11 | Cost-effectiveness of interferon gamma in the treatment of community-acquired pneumonia in a hospital | Medicine. 2020;8(1):93-101 | Plavinskii S.L., Shabalkin P.I. |
| 12 | Practice Patterns and Outcomes of Online Hemodiafiltration: A Real-World Evidence Study in a Russian Dialysis Network | Blood Purif. 2020 Sep 23:1-10. DOI: 10.1159/000510551 | Neri L, Gurevich K, Zarya Y, Plavinskii S, Bellocchio F, Stuard S, Barbieri C, Canaud B. |
| 13 | The concept of chronic obstructive pulmonary disease clinical control as a decision-making tool in real clinical practice for optimizing of basic pharmacotherapy | Ter Arkh. 2020;92(1):89-95. DOI: 10.26442/00403660.2020.01.000489 | Avdeev S.N., Aisanov Z.R., Belevsky A.S., Bi K.M., Vizel A.A., Zyryanov S.K., Ignatova G.L., Kostikas K., Leshchenko I.V., Ovcharenko S.I., Sinopalnikov A.I., Titova O.N., Shmelev E.I. |
| 14 | The Pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia | S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6-2):82-91 | Zyryanov S.K., Dyakov I.N., Zhuperin A.A., Egorova D.A., Mosolova E.S. |
| 15 | Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure | Russian Journal of Cardiology. 2020;25(1):65-71. (In Russ.) DOI: 10.15829/1560-4071-2020-1-3690 | Zyryanov S.K., Ushkalova E.A. |
| 16 | Clinical recommendations in the light of new legislation | RMJ. 2020;28(6):15-19 | Kazakov A.S., Zyryanov S.K., Ushkalova E.A. |
| 17 | Prevalence and risk factors of potentially prescribing omissions in elderly and senile patients: clinical practice in Russian hospitals | Adv Gerontol. 2020;33(2):282-288. PMID: 32593242 | Al-Ragawi A.M., Zyryanov S.K., Ushkalova E.A., Butranova O.I., Pereverzev A.P. |
| 18 | Pharmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation | Good Clinical Practice. 2020;(3):40-51. DOI: 10.37489/2588-0519-2020-3-40-51 | Lila A.M., Zyryanov S.K., Dyakov I.N. |
| 19 | Management of treatment on the basis of adherence. Consensus document – Clinical recommendations. RSMSIM, SSGR, NATH, SEBN, GS RAS, RSH, RSP | Consilium Medicum. 2020;22(5):9–18. DOI: 10.26442/20751753.2020.5.200078 | Nikolaev N.A., Martynov A.I., Skirdenko Iu.P., Anisimov V.N., Vasil'eva I.A., Vinogradov O.I., Lazebnik L.B., Poddubnaya I.V., Roitman E.V., Ershov A.V., et al. |
| 20 | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(1):5-12. DOI: 10.17749/2070-4909.2020.13.1.5-12 | Zyryanov S.K., Diyakov I.N. |
| 21 | Economic challenges of oncological diseases’ pharmacotherapy | FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(1):64-70. DOI: 10.17749/2070-4909.2020.13.1.64-70 | Ushkalova E.A., Zyryanov S.K., Gopienko I.A. |
| 22 | Pharmacoeconomic evaluation of ceftazidime + avibactam administration in the treatment of nosocomial pneumonia caused by carbapenem-resistant Enterobacteriacea and complicated by bacteremia | Medical Technologies. Assessment and choice. 2020;(2): 50-58. DOI 10.17116/medtech20204002150 | Zyryanov S.K., Dyakov I.N. |
| 23 | Pharmacoeconomic evaluation of treatment options for patients with moderate to severe psoriasis and resistance to basic systemic therapy | Clinical Pharmacology and Therapy. 2018;27(4):91-97.  | Zyryanov S.K., Cheberda A.E., Belousov D.Yu. |
| 24 | An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. | Russian Journal of Infection and Immunity. 2020;10(2):277-286. (In Russ.) DOI: 10.15789/2220-7619-AEA-1458 | Kolbin A.S. |
| 25 | Socio-economic burden of COVID-19 in the Russian Federation | Good Clinical Practice. 2020;(1):35-44. (In Russ.) DOI: 10.37489/2588-0519-2020-1-35-44 | Kolbin A.S., Belousov D.Yu., Gomon Yu.M., Balykina Yu.E., Ivanov I.G. |
| 26 | Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer | Good Clinical Practice. 2020;(1):4-21. (In Russ.) DOI: 10.37489/2588-0519-2020-1-4-21 | Kolbin A.S., Vilyum I.A., Proskurin M.A., Balikina Yu.E., Pavlysh A.V. |
| 27 | Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis | Good Clinical Practice. 2020;(1):23-34. (In Russ.) DOI: 10.37489/2588-0519-2020-1-23-33 | Kolbin A.S., Kurylev A.A., Mishinova S.A., Balykina Yu.E., Proskurin M.A. |
| 28 | Pragmatic clinical trials | Good Clinical Practice. 2020;(3):52-60. (In Russ.) DOI: 10.37489/2588-0519-2020-3-52-60 | Shevchenko O.R., Kolbin A.S. |
| 29 | Socio-Economic Burden of COVID-19 in Russian Federation | Value in Health, 2020, Vol. 23, S556. DOI: 10.1016/j.jval.2020.08.906 | Kolbin A., Gomon J., Balykina Y., Belousov D., Ivanov I. |
| 30 | Using Epidemiological Real-World Datа in Assessing the Socio-Economic Burden of HIV and the Clinical and Economic Aspects of Antiretroviral Therapy | Value in Health, 2020, Vol. 23, S572. DOI: 10.1016/j.jval.2020.08.1010 | Kolbin A., Velum I., Balykina Y., Proskurin M. |
| 31 | Health-Economic Analysis of Tocilizumab in Patients with Rheumatoid Arthritis and Systemic Juvenile Arthritis | Value in Health, 2020, Vol. 23, S599. DOI: 10.1016/j.jval.2020.08.1168 | Kolbin A., Kurylev A., Balykina Y., Proskurin M., Mishinova S. |
| 32 | The Burden of Spinal Muscular Atrophy in Russia | Value in Health, 2020, Vol. 23, S632. DOI: 10.1016/j.jval.2020.08.1377 | Kolbin A., Kurylev A., Balykina Y., Proskurin M., Mishinova S. |
| 33 | Pharmacoeconomic Prospects for the Use of Ravulizumab in the Treatment of Paroxysmal Nocturnal Hemoglobinuria | Value in Health, 2020, Vol. 23, S694. DOI: 10.1016/j.jval.2020.08.1763 | Kolbin A., Velum I., Balykina Y., Proskurin M. |
| 34 | Clinical and economic rationale for screening for Pompe disease in children in domestic conditions | Good Clinical Practice. 2020;(5):27-37. DOI: 10.37489/2588-0519-2020-5-27-37 | Kolbin A.S., Vilyum I.A., Balykina Yu.E., Proskurin M.A., Karpov O.I. |
| 35 | The first domestic risk calculator for prediabetes and type 2 diabetes | Diabetes Mellitus. 2020;(6) In print | Shestakova M.V., Kolbin A.S., Galstyan G.R., Arepyeva M.A., Zaitseva E.L., Mayorov A.Yu., Karpov O.I., Proskurin M.A., Kurylev A A.A. Dedov I.I. |
| 36 | Legal aspects of conducting research on real-world clinical practice | Good Clinical Practice. 2020;(5):27-32. DOI: 10.37489/2588-0519-2020-5-27-32 | Sikachev V.V., Gorin V.V., Kolbin A.S., Belousov D.Yu. |

**II. Oral and Poster Presentations on Pharmacoeconomics and Health Technology Assessment at the ISPOR International and European Meetings**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| № | Conference Title | Organizers | Report Title | Date | Venue |
| 1 | ISPOR Europe 2020 | ISPOR | Cost-Effectiveness Analysis of Universal Vaccination with Pentavalent Vaccine in Russia | November 16-19, 2020 | Virtual |
| 2 | ISPOR Europe 2020 | ISPOR | Cost Analysis of Russian Immunization Program - Opportunities for Investment | November 16-19, 2020 | Virtual |
| 3 | ISPOR Europe 2020 | ISPOR | Socio-Economic Burden of COVID-19 in Russian Federation | November 16-19, 2020 | Virtual |
| 4 | ISPOR Europe 2020 | ISPOR | Using Epidemiological Real-World Datа in Assessing the Socio-Economic Burden of HIV and the Clinical and Economic Aspects of Antiretroviral Therapy | November 16-19, 2020 | Virtual |
| 5 | ISPOR Europe 2020 | ISPOR | Health-Economic Analysis of Tocilizumab in Patients with Rheumatoid Arthritis and Systemic Juvenile Arthritis | November 16-19, 2020 | Virtual |
| 6 | ISPOR Europe 2020 | ISPOR | The Burden of Spinal Muscular Atrophy in Russia | November 16-19, 2020 | Virtual |
| 7 | ISPOR Europe 2020 | ISPOR | Pharmacoeconomic Prospects for the Use of Ravulizumab in the Treatment of Paroxysmal Nocturnal Hemoglobinuria | November 16-19, 2020 | Virtual |

**III. Oral Presentations in the Field of Pharmacoeconomics and Health Technology Assessment at Russian and International Conferences**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| № | Conference Title | Organizers | Report Title | Dates | Venue |
| 1 | XV International Congress on Electrostimulation and Clinical Electrophysiology of the Heart "Cardiostim-2020" | Ministry of Health of the Russian Federation (MH RF), All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Cardiac Stimulation, Russian Society of Cardiology, All-Russian Society of Surgeons | Pharmacoeconomic aspects of vaccination against pneumococcal infection in patients with cardiovascular system diseases | February 27-29, 2020 | Saint Petersburg |
| 2 | VI St. Petersburg International Oncology Forum “White Nights 2019” | Ministry of Health of the Russian Federation (MH RF); Russian Society of Clinical Oncology (RUSSCO) | Pharmacoeconomic aspects of vaccination against pneumococcal infection in cancer patients in the Russian Federation | June 25-28, 2020 | Saint Petersburg |
| 3 | XXII Congress of Pediatricians of Russia with international participation “Actual Problems of Pediatrics” | Union of pediatricians of Russia | Pharmacoeconomic aspects of vaccination against rotavirus infection in the Russian Federation. | February 21-23, 2020 | Moscow |
| 4 | Joint scientific and practical conference with international participation ‘HIV- infection and immunosuppression. Issues of epidemiology, pharmacoeconomics and clinics of viral infections’ | Russian Academy of Sciences (RAS); Ministry of Health of the Russian Federation; Federal Service for the Oversight of Consumer Protection and Welfare | Pharmacoeconomic aspects of chronic hepatitis C therapy | November 19, 2020 | Saint Petersburg |
| 5 | Interregional scientific-practical conference "Interdisciplinary issues of vaccine prevention in different age groups" | Department of Health of the Tomsk Region | Pharmacoeconomic analysis of adult vaccination against pneumococcal infection | October 16, 2020 | Tomsk |
| 6 | XI All-Russian Congress of Patients “Vector of Development: Patient-Focused Health Care” | Russian Patients Association | Pharmacoeconomic aspects of innovative therapy for CLL | November 26-29, 2020 | Moscow |
| 7 | Annual Moscow City Conference dedicated to pressing issues of clinical pharmacology and pediatrics “Medicine and Children” | Moscow Department of Health | Pharmacoeconomic aspects of children vaccination against rotavirus infection | September 17, 2020 | Moscow |
| 8 | Panel discussion‘Management tactics of patients with respiratory diseases at the stage of primary health care: focus on vaccine prevention’ | Russian Society for the Prevention of Noncommunicable Diseases | Pharmacoeconomic aspects of vaccination against pneumococcal infection | October 7, 2020 | Moscow |
| 9 | All-Russian Congress with international participation “Days of Rheumatology in St. Petersburg-2020” | MH RF; Association of Rheumatologists of Russia (ARR) | Pharmacoeconomic aspects of rheumatoid arthritis therapy with upadacitinib | October 15-16, 2020 | Saint Petersburg |
| 10 | Seminar ‘Diabetes Mellitus: Time for New Solutions’ | PSMU | Clinical and economic aspects of modern methods of type 2 diabetes mellitus control | March 16, 2020 | Vladivostok |
| 11 | XV International Scientific Congress “Rational Pharmacotherapy” | Association of Clinical Pharmacologists of the Northwest | Clinical and economic characteristics of effective control of severe bronchial asthma | October 16, 2020 | Saint Petersburg |
| 12 | V Interregional Scientific and Practical Conference ‘From Clinical Recommendations to Clinical Algorithms’ | Association of Clinical Pharmacologists | Clinical and economic substantiation of effective control of severe bronchial asthma | December 10, 2020 | Volgograd |
| 13 | V Interregional Scientific and Practical Conference ‘From Clinical Recommendations to Clinical Algorithms’ | Association of Clinical Pharmacologists | Clinical and economic aspects of modern methods of type 2 diabetes mellitus control | December 10, 2020 | Volgograd |
| 14 | City conference “Elderly patient. Unsolved problems of diagnosis and treatment” |  | Pharmacoeconomic aspects of diabetes mellitus treatment using SGLT-2 inhibitors | February 2, 2020 | Moscow |
| 15 | XXVII Russian National Congress “Man and Medicine” |  | Problems of prescribing drugs in populations of patients of extreme age groups | April 6-9, 2020 | Moscow |
| 16 | VI Annual Moscow Congress “Votchalov Readings” |  | Pharmacoeconomic rationale for drug therapy of CHF in patients after hospitalization for decompensation of the disease | May 28, 2020 | Moscow |
| 17 | VI Annual Moscow Congress “Votchalov Readings” |  | Pharmacoeconomic aspects in the treatment of patients with multiple sclerosis | May 28, 2020 | Moscow |
| 18 | VI Annual Moscow Congress “Votchalov Readings” |  | Comparative review of anti-IL drugs included in VED list for the treatment of patients with severe asthma | May 28, 2020 | Moscow |
| 19 | Conference “Week of Antimicrobial Therapy and Clinical Microbiology” |  | Optimizing Antibiotic Costs: Smart Savings | October 7-13, 2020 | Smolensk, online |
| 20 | V Privolzhsk conference on antimicrobial therapy and clinical microbiology with international participation |  | Optimizing Antibiotic Costs: Smart Savings | October 8-9, 2020 | Nizhny Novgorod, online |
| 21 | V Central Russian Conference on Antimicrobial Therapy and Clinical Microbiology |  | Introducing new antibiotics into clinical practice: how to reach a consensus between needs and opportunities? | October 15-16, 2020 | Belgorod, online |
| 22 | XXIY Annual Scientific Session of the Institute of Pharmacology named after A. V. Waldman | MH RF | Current state of real world data. What is RWD / RWE? | January 24, 2020 | Saint Petersburg |
| 23 | “Cardiostim” Congress | MH RF | General questions of real-world clinical practice | February 29, 2020 | Saint Petersburg |
| 24 | 7th Interregional Scientific and Practical Symposium “Pharmacoeconomics of Chronic Viral Infections. Economic Issues in Epidemiology, Prevention, Diagnostics and Clinic of HIV Infection and Chronic Hepatitis” | MH RF; RAS | Real world data and other terms. What do we know about it? | April 21, 2020 | Saint Petersburg |
| 25 | IV Interregional Scientific and Practical Conference “From Clinical Recommendations to Clinical Algorithms” | MH RF;Volgograd State Medical University | Real-world clinical practice questions (RWD and RWE). Place and role of clinical pharmacology | May 18, 2020 | Volgograd |
| 26 | International online seminar “Broadcasting evidence-based medical knowledge” | MH RF;Russian Medical Postgraduate Academy | Evidence-Based Medicine: Real-World Data vs Evidence-Based Medicine | May 29, 2020 | Moscow |
| 27 | VI St. Petersburg International Oncology Forum “White Nights 2020” | MH RF;RAS | Data from real-world clinical practice. From glossary to practical application in oncology | June 25, 2020 | Saint Petersburg |
| 28 | VII St. Petersburg Septic Forum 2020 and the Interregional Joint Scientific and Practical Conference “Janelidze Readings” | St. Petersburg Health Committee;Territorial Compulsory Medical Insurance Fund of St. Petersburg;Saint Petersburg Research Institute of Emergency Medicine n.a. I.I. Dzhanelidze | Pharmacoepidemiology of the use of antibacterial agents in St. Petersburg | September 10, 2020 | Saint Petersburg |
| 29 | Future-proof healthcare technologies | MH RF | RWD / RWE: evidence of real-world clinical practice, current state of the art in the world | September 23, 2020 | N. Novgorod |
| 30 | RWD / RWE: an essential tool for the healthcare decision making | Association of HTA Professionals;ISPOR | RWD / RWE: real-world clinical practice research, state of the art | September 24, 2020 | Moscow |
| 31 | Joint scientific and practical conference with international participation “HIV infection and immunosuppression. Issues of epidemiology, pharmacoeconomics and clinics of viral infections” | RAS;MH RF | The role of RWD / RWE in pharmacoeconomics | November 20, 2020 | Saint Petersburg |
| 32 | Clinical trials in Russia | The Adam Smith Institute | The current state of RWD / RWE in Russia. View from the perspective of clinical pharmacology | December 1, 2020 | Moscow |
| 33 | V Interregional Scientific and Practical Conference ‘From Clinical Recommendations to Clinical Algorithms’ | Association of Clinical Pharmacologists | What tools do we have for measuring RWD? | December 10, 2020 | Volgograd |

**IV. ISPOR Chapter Journal**

Good Clinical Practice. www.clinvest.ru

**V. Branch Interaction with Authorities**

1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health
2. Participation in the Working Group of experts of the Russian Federation Ministry of Health on immunoprophylaxis of infectious diseases

**VI. Chapter Interaction with Professional Organizations**

1. Participation in the work of the All-Russian Association of Clinical Pharmacologists
2. Participation in the work of the Educational and Methodical Committee on Clinical Pharmacology under the Russian Federation Ministry of Health
3. Participation in the work of the Independent Council of the Union of Experts in the Field of Immunoprophilaxis.

**VII. Chapter Websites**

* http://www.labclinpharm.ru
* http://www.healtheconomics.ru
* http://hta.labclinpharm.ru
* YouTube channel: https://www.youtube.com/playlist?list=PLrajN8RdElYoRDKBcWVdhyawjsTJ8rUlQ

**VIII. Participation in International Grants and Nominations**

ISPOR Russia St. Petersburg Chapter won the “ISPOR Outstanding Regional Chapter” Award in the ISPOR Small Chapter category (10-40 Chapter members). The award ceremony was held on November 5 in Copenhagen as a part of the ISPOR Europe Conference.

**IX. Educational Programs and Seminars**

1. On the base of Pavlov First Saint Petersburg State Medical University, an educational course for doctors was organized within the framework of continuous medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): “Current issues of Health Technology Assessment”, October 2020
2. At the North-West State Medical University named after I.I. Mechnikov, the issues of health technologies assessment were introduced into the Master’s degree programs with major in Public Health, and included in the residency program majoring in Healthcare Organization and Public Health.
3. At the St. Petersburg State Chemical and Pharmaceutical University, the “Pharmacoeconomic Analysis” course is included in the basic part of the training program for residents in the specialty “Management and Economics of Pharmacy”, the course “Fundamentals of Pharmacoeconomics” is included in the educational program for students of the Faculty of Pharmacy with major in Pharmacy, the course “Pharmacoeconomics of innovative drugs” is included in the educational Master’s degree program in the specialties “Chemistry” and “Biotechnology”.
4. The following Recommendations were developed and published:

Research of real-world clinical practice. - M.: OKI Publishing House: Buki Vedi, 2020. – 208 p. ISBN 978-5-4465-2902-5 / A.S. Kolbin, D.Yu. Belousov, S.K. Zyryanov, V.V. Omelyanovskiy, D.A. Sychev, A.L. Khokhlov, S.L. Plavinsky, B.K. Romanov, M.V. Zhuravleva, E.V. Verbitskaya, E.A. Volskaya, D.A. Rozhdestvensky, S.V. Glagolev, M. Yu. Frolov, A.V. Rudakova, A.V. Pavlysh, Yu.E. Balykina, A.A. Kurylev, A.V. Ivanov, D.S. Kozlov, S.B. Vasilchenko, T.I. Galimov, O.A. Loginovskaya, S.A. Mishinova, T.A. Goldin, V.A. Bulatov, E.V. Lavrent'ev, V.V. Gorin, L.A. Khudova, V.V. Sekachev, I. V. Efimenko, L.I. Karpenko, A.A. Polikarova

**X. Organizational Work**

1. Within the framework of the XXIY annual scientific session of the Institute of Pharmacology named after A.V. Waldman the section “Current State of Real World Data. What is RWD / RWE?” was organized and held in St. Petersburg on January 24, 2020.
2. Within the framework of the “Cardiostim” Congress, a section “General Questions of Real-World Clinical Practice” was organized and held in St. Petersburg on February 29, 2020.
3. Within the framework of the VII Interregional Scientific and Practical Symposium “Pharmacoeconomics of Chronic Viral Infections. Economic Issues in Epidemiology, Prevention, Diagnostics and Clinics of HIV Infection and Chronic Hepatitis”, a section “Real World Data and Other Terms. What Do We Know About This? ” was organized and held in St. Petersburg on April 21, 2020.
4. Within the framework of the VI St. Petersburg International Forum on Oncology, the section “Data from Real-World Clinical Practice. From a Glossary to Practical Applications in Oncology ” was organized and held in St. Petersburg on July 25, 2020.
5. The international conference “RWD / RWE is an Important Tool for Decision-making in Healthcare” was organized and held in Moscow on September 24, 2020.
6. Within the framework of the Scientific and Practical Conference with international participation “HIV infection and immunosuppression. Issues of epidemiology, pharmacoeconomics and clinics of viral infections”, the section “RWD / RWE and Its Role in Pharmacoeconomics” was organized and held in St. Petersburg on November 20, 2020.

**XI. Chapter Plans for the Future**

1. The development of the Concept for the Regulation of Research on Real-World Clinical Practice Data (RWD / RWE) within the framework of the Eurasian Economic Union.